Loss of signal transducer and activator of transcription 1 is associated with prostate cancer recurrence
- 23 October 2015
- journal article
- research article
- Published by Wiley in Molecular Carcinogenesis
- Vol. 55 (11) , 1667-1677
Abstract
STAT1 loss has previously been implicated in cell line studies to modify prostate cancer cell growth and survival, however the clinical significance of this has not previously been established. This study investigated if STAT1 loss was associated with patient outcome measures and the phenotypic consequence of STAT1 silencing. STAT1 expression was assessed in two patient cohorts with localised (n = 78) and advanced prostate cancer at initial diagnosis (n = 39) by immunohistochemistry (IHC). Impact of STAT1 silencing on prostate cancer cells lines was assessed using Cell Death detection ELISA, TLDA gene signature apoptosis arrays, WST-1 assay, xCELLigence system, clonogenic assay, and wound healing assay. In the localised patient cohort, low expression of STAT1 was associated with shorter time to disease recurrence (3.8 vs 7.3 years, P = 0.02) and disease specific survival (6.6 vs 9.3 years, P = 0.05). In the advanced patient cohort, low expression was associated with shorter time to disease recurrence (2.0 vs 3.9 years, P = 0.001). When STAT1 was silenced in PC3 cells (AR negative) and LNCaP cells (AR positive) silencing did not influence levels of apoptosis in either cell line and had little effect on cell viability in the LNCaP cells. In contrast, STAT1 silencing in the PC3 cells resulted in a pronounced increase in cell viability (WST-1 assay: mock silenced vs STAT1 silenced, P < 0.001), clonagenicity (clonogenic assay: mock silenced vs STAT1 silenced, P < 0.001), and migration (wound healing: mock silenced vs STAT1 silenced, P < 0.001). In conclusion, loss of STAT1 may promote prostate cancer recurrence in AR negative patients via increasing cell viability.Keywords
Funding Information
- Prostate Cancer UK (PG10-15)
This publication has 29 references indexed in Scilit:
- Prostate cancer: ESMO Consensus Conference Guidelines 2012Annals of Oncology, 2013
- Optimizing the care of patients with advanced prostate cancer in the UK: current challenges and future opportunitiesBJU International, 2012
- STAT1-deficient mice spontaneously develop estrogen receptor α-positive luminal mammary carcinomasBreast Cancer Research, 2012
- Cooperation between Stat3 and Akt Signaling Leads to Prostate Tumor Development in Transgenic MiceNeoplasia, 2011
- SOCS-3 antagonises the proliferative and migratory effects of fibroblast growth factor-2 in prostate cancer by inhibition of p44/p42 MAPK signallingEndocrine-Related Cancer, 2010
- Expression levels of the JAK/STAT pathway in the transition from hormone-sensitive to hormone-refractory prostate cancerBritish Journal of Cancer, 2007
- STAT1-induced Apoptosis Is Mediated by Caspases 2, 3, and 7Journal of Biological Chemistry, 2004
- IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicityNature, 2001
- Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent miceProceedings of the National Academy of Sciences, 1998
- Activation of the STAT Signaling Pathway Can Cause Expression of Caspase 1 and ApoptosisMolecular and Cellular Biology, 1997